Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the highest dose of levodopa/carbidopa that can be
tolerated without any serious side effects by children with Angelman syndrome.
It has been hypothesized that levodopa may lead to an improvement in the neurodevelopment and
abnormal movements (e.g. tremors) in children with Angelman syndrome.
Data from this study will be used to design a phase II trial to determine the efficacy of
levodopa in treating children with Angelman syndrome.
Phase:
Phase 1
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa